Well from the sound of it CF33 makes the old scale redundent.
I think it is far from clear that her-vaxx isnt worth the trouble. They are in negotiations. The market is slow and having $150m in cash they dont need to hurry. I heard in one of these threads that the most advanced trial on her-vaxx had only 19 patients. More data is need to get deals made.
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-159
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $443.4K | 8.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 3056419 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |